Cargando…
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
BRCA1-mutated breast cancer is primarily driven by DNA copy-number alterations (CNAs) containing large numbers of candidate driver genes. Validation of these candidates requires novel approaches for high-throughput in vivo perturbation of gene function. Here we develop genetically engineered mouse m...
Autores principales: | Annunziato, Stefano, de Ruiter, Julian R., Henneman, Linda, Brambillasca, Chiara S., Lutz, Catrin, Vaillant, François, Ferrante, Federica, Drenth, Anne Paulien, van der Burg, Eline, Siteur, Bjørn, van Gerwen, Bas, de Bruijn, Roebi, van Miltenburg, Martine H., Huijbers, Ivo J., van de Ven, Marieke, Visvader, Jane E., Lindeman, Geoffrey J., Wessels, Lodewyk F. A., Jonkers, Jos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344487/ https://www.ncbi.nlm.nih.gov/pubmed/30674894 http://dx.doi.org/10.1038/s41467-019-08301-2 |
Ejemplares similares
-
TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development
por: Cornelissen, Lisette M., et al.
Publicado: (2020) -
Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland
por: Annunziato, Stefano, et al.
Publicado: (2016) -
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
por: Zimmerli, Dario, et al.
Publicado: (2022) -
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
por: Zingg, Daniel, et al.
Publicado: (2022) -
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
por: Zingg, Daniel, et al.
Publicado: (2022)